 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

---
- Zacks Investment Research upgraded shares of PLx Pharma (NASDAQ:PLXP) from a hold
  rating to a buy rating in a research report released on Friday, Zacks.com reports.
  Zacks Investment Research currently has $20.00 price target on the biotechnology
  companys stock. According to Zacks, PLx Pharma Inc. is...


PLx Pharma (NASDAQ:PLXP) Lifted to Buy at Zacks Investment Research

---
- Zacks Investment Research upgraded shares of PLx Pharma (NASDAQ:PLXP) from a hold
  rating to a buy rating in a research note released on Thursday, Zacks.com reports.
  They currently have $22.00 price objective on the biotechnology companys stock.
  According to Zacks, PLx Pharma Inc. is a specialty ...


PLx Pharma (NASDAQ:PLXP) Rating Increased to Buy at Zacks Investment Research

---
- PLx Pharma (PLXP) is seeing favorable earnings estimate revision activity and has
  a positive Zacks Earnings ESP heading into earnings season.
- ''
- " Want the latest recommendations from Zacks Investment Research? Today, you can
  download 7 Best Stocks for the Next 30 Days. Click to get this free report&..."


Is a Surprise Coming for PLx Pharma (PLXP) This Earnings Season?

---
- Zacks Investment Research upgraded shares of PLx Pharma (NASDAQ:PLXP) from a sell
  rating to a hold rating in a research note published on Tuesday, Zacks.com reports.
  According to Zacks, PLx Pharma Inc. is a specialty pharmaceutical company. It focused
  on developing clinically validated and patent-...


PLx Pharma (NASDAQ:PLXP) Upgraded to "Hold" at Zacks Investment Research

---
- PLx Pharma (NASDAQ:PLXP) was downgraded by Zacks Investment Research from a hold
  rating to a sell rating in a research report issued to clients and investors on
  Wednesday, Zacks.com reports. According to Zacks, PLx Pharma Inc. is a specialty
  pharmaceutical company...


PLx Pharma (NASDAQ:PLXP) Cut to "Sell" at Zacks Investment Research

---
- Zacks Investment Research upgraded shares of PLx Pharma (NASDAQ:PLXP) from a sell
  rating to a hold rating in a report published on Saturday, Zacks.com reports. According
  to Zacks, PLx Pharma Inc. is a specialty pharmaceutical company. It focused on developing
  clinically validated and patent-...


PLx Pharma (NASDAQ:PLXP) Upgraded to Hold by Zacks Investment Research

---
- PLx Pharma (NASDAQ:PLXP) was downgraded by Zacks Investment Research from a hold
  rating to a sell rating in a report issued on Saturday, Zacks.com reports. According
  to Zacks, PLx Pharma Inc. is a specialty pharmaceutical company. It focused on developing
  clinically validated and patent-protected ...


Zacks Investment Research Downgrades PLx Pharma (NASDAQ:PLXP) to Sell

---
- Zacks Investment Research cut shares of PLx Pharma (NASDAQ:PLXP) from a buy rating
  to a hold rating in a report issued on Thursday, Zacks.com reports. According to
  Zacks, PLx Pharma Inc. is a specialty pharmaceutical company. It focused on developing
  clinically validated and patent-protected ...


PLx Pharma (NASDAQ:PLXP) Downgraded by Zacks Investment Research

---
- PLx Pharma (NASDAQ:PLXP) was upgraded by Zacks Investment Research from a hold rating
  to a buy rating in a research note issued on Friday, Zacks.com reports. The firm
  presently has a $3.00 target price on the biotechnology companys stock. Zacks Investment
  Researchs target price would indicate a ...


---
- NEW YORK, Jan. 25, 2017 /PRNewswire/ -- Juan Monteverde, founder and managing partner
  at Monteverde & Associates PC, a boutique securities firm headquartered at the Empire
  State Building in New York City, is investigating Dipexium Pharmaceuticals, Inc.
  ("Dipexium" or the "Company")(DPRX) and its Board of Directors for potential federal
  law violations and/or breaches of fiduciary duties in connection the acquisition
  of PLx Pharma Inc. (the "Merger").
- The investigation focuses on whether Dipexium and/or its Board of Directors violated
  federal securities laws and/or breached their fiduciary duties to the Company's
  stockholders by 1) failing to properly value the Merger and 2) failing to disclose
  all material information in connection with the Merger.
- Monteverde & Associates PC is a boutique class action securities and consumer litigation
  law firm committed to protecting shareholders and consumers from corporate wrongdoing.
- |-
  MONTEVERDE & ASSOCIATES PC

   The Empire State Building

   350 Fifth Ave. 59th Floor

   New York, NY 10118

   United States of America

    Tel: (212) 971-1341

  Attorney Advertising.
- The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com).


Watchers	1,581
52-Wk Low	$1.34
52-Wk High	$142.01

Market Cap	$8.21M
Volume (M)	144,261.00
52-Wk High	$142.01
52-Wk Low	$1.34

DPRX Dipexium Pharmaceuticals Inc.

About

Feed

News

Fundamentals